Laboratory of neurophysiology, Biology Department, University of the Balearic Islands, Health Research Institute of the Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Spain.
Research Group on Community Nutrition and Oxidative Stress (NUCOX), Health Research Institute of the Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands, Spain.
Curr Pharm Des. 2021;27(22):2558-2570. doi: 10.2174/1381612826666200417165801.
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, directly related to the progressive increase in body weight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response and oxidative stress in hepatocytes and alteration of the circulating lipid and glycaemic profile. However, to date, there are no effective pharmacological treatments for patients with NAFLD. Lifestyle changes and dietary modifications aimed at weight loss are the best current alternatives; therefore, new approaches should be considered. Resveratrol, a natural polyphenol of the stilbene group, is a potential candidate for the management of NAFLD for its anti-inflammatory, antioxidant properties, and calorie restriction-like effects.
In this review, the available information on the potential therapeutic effects of resveratrol on NAFLD, found mainly in animal models and in some clinical trials, is summarizes.
In vitro and animal model studies have shown beneficial effects of resveratrol treatment on NAFLD. Resveratrol reduces the hepatic accumulation of lipids and improves lipid and glycaemic metabolism. Some of the mechanisms of action are the signalling pathways of AMP-activated protein kinase, sirtuin 1 and nuclear factor κB. However, the results obtained in clinical trials are inconclusive.
Although preclinical trials have shown promising results of resveratrol against NALFD, the lack of clear results in clinical trials makes it necessary to conduct more studies with a larger number of patients and for a longer time.
非酒精性脂肪性肝病（NAFLD）是全球最常见的慢性肝病病因之一，与体重和肥胖的逐渐增加直接相关。NAFLD 患者的脂质积累导致肝细胞中胰岛素抵抗、炎症反应和氧化应激的发展，以及循环脂质和血糖谱的改变。然而，迄今为止，NAFLD 患者尚无有效的药物治疗方法。旨在减肥的生活方式改变和饮食调整是目前最好的替代方法；因此，应该考虑新的方法。白藜芦醇是一种天然的芪类多酚，具有抗炎、抗氧化特性和类似热量限制的作用，是治疗 NAFLD 的潜在候选药物。
本文综述了白藜芦醇对 NAFLD 的潜在治疗作用的现有信息，这些信息主要来自动物模型和一些临床试验。
体外和动物模型研究表明，白藜芦醇治疗 NAFLD 具有有益作用。白藜芦醇可减少肝脏脂质堆积，改善脂质和血糖代谢。其作用机制之一是 AMP 激活蛋白激酶、SIRT1 和核因子 κB 的信号通路。然而，临床试验的结果并不一致。
尽管临床前试验表明白藜芦醇对 NALFD 有一定的治疗作用，但临床试验中缺乏明确的结果，使得有必要进行更多的、更大规模的、更长时间的研究。
